Invitrocue currently operates in Singapore, Australia, China, Hong Kong and Germany,

and is listed on Australian Securities Exchange under the ticker IVQ.

Invitrocue Limited (ASX:IVQ)

Welcome

Leader in Personal Oncology Testing

Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases.

In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalized oncology testing).

About Us

News & Events

12 Oct 2020
Webinar – New Trends in Drug Discovery : Robotics and AI

The drug discovery ecosystem is changing rapidly. The rise of robotics and AI enables the emergence of a new model of data-driven drug discovery. Bringing together recent advances in life sciences automation and machine learning applications for drug discovery, new partnerships evolve that allow for game-changing improvements in the drug discovery process. The webinar will […]

Read More
30 Apr 2020
Onco-PDO cancer test successfully registered for CE Mark

Onco-PDO cancer test successfully registered for CE Mark

Read More
11 Dec 2019
The war against cancer will be fought better with improved decision making tools

Excerpt: The number of people living with cancer continues to grow around the world. The World Health Organisation predicts next year there will be 4.5 million new cancer cases and 6.7 million by 2040 – and that’s just in China. Globally there are 15 million today. “Cancer is affecting everybody – almost everyone knows someone […]

Read More
21 Oct 2019
Invitrocue Establishes Hong Kong Laboratory

Invitrocue Establishes Hong Kong Laboratory Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce the establishment of laboratory facility in Hong Kong. The Hong Kong facility, which will be used for research and development and for commercial purposes, provides Invitrocue with better access to the network of supportive […]

Read More
21 Oct 2019
Invitrocue Clinical Studies underway in Germany

Invitrocue Clinical Studies underway in Germany Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce that a clinical validation study is underway for its Onco-PDO test with Klinikum Rechts der Isar der Technischen Universitat Munchen, Comprehensive Cancer Center Munich, Germany.

Read More
09 Sep 2019
Collaboration with National University Hospital Singapore

Collaboration with National University Hospital Singapore 08 August, 2019: Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the commencement of a clinical validation collaboration with National University Hospital (NUH), a leading public teaching hospital in Singapore. The aim of the clinical study is to validate Invitrocue’s Onco-PDO drug screening […]

Read More
06 May 2019
Invitrocue Appoints Global Insurance Advisor

IVQ Appoints Global Insurance Advisor 06 May, 2019: Innovative life sciences company Invitrocue Limited (ASX: IVQ), (‘Invitrocue’ or ‘the Company’), is please to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor. In his role at Invitrocue, Dato Dr Wahab will advise and support the Company’s global insurance strategy for its Onco […]

Read More
19 Feb 2019
Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

EXCERPT:  February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an […]

Read More
11 Feb 2019
Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

EXCERPT:  February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system […]

Read More
23 Jan 2019
IVQ technology development agreement with SIBCB on breast cancer.

EXCERPT: January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDO® […]

Read More